2 November 2021 at 9:00 a.m. (EET)
Nightingale Health Plc (”Nightingale”) has appointed Tuukka Paavola as Chief Financial Officer. Paavola will join Nightingale’s management team as of 1 January 2022 at the latest.
Tuukka Paavola has held several leadership positions related to finance, business development and strategy for more than 15 years. Paavola joins Nightingale from Nordea’s Group Strategy Office, where he held the position of First Vice President, directly supporting the Group CEO and CFO. Before that he was the Head of CEO Office at Nordea, supporting the Board of Directors and the Group Leadership Team in strategic, tactical and operational matters. He holds a master’s degree in industrial engineering and is a Chartered Financial Analyst (CFA) charterholder. At Nightingale, Paavola will have a key role in taking leadership of the finance function and implementing Nightingale’s international growth strategy.
Nightingale’s current interim Chief Financial Officer Laura Pulkkinen who was appointed to lead Nightingale’s finance function in the transition from private company into public company will return to her previous role in enabling Nightingale’s growth by heading key business initiatives.
Teemu Suna, CEO and co-founder of Nightingale:
“Laura exceeded all expectations in transforming Nightingale’s finance function to a level required from a public company and she has created an excellent foundation to continue future development of Nightingale’s financial operations. We are delighted to have Laura back in our key business initiatives and to announce that Tuukka Paavola will join Nightingale as the new CFO. Tuukka’s work history and achievements are impressive, and he has demonstrated the needed skills and attitude to reach ambitious goals under high pressure. I am confident that his background from vice president positions in finance coupled with business leadership will contribute to Nightingale’s success.”
“I am excited to join Nightingale as the CFO and to be part of the mission to bring tools for longer, healthier life available for everyone. Nightingale’s technology has a game-changing potential, and the demand for Nightingale’s products is already proven with several commercial agreements and other milestones the company has announced after the IPO. I look forward to working with Nightingale’s team in realising the commercial potential and growth opportunities.”
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.